Core Viewpoint - The company announced a profit distribution plan for the first three quarters of 2025, which includes a cash dividend of 0.3 yuan per share (tax included) [2] Summary by Sections - **Dividend Details** - The cash dividend of 0.3 yuan per share will be distributed to shareholders [2] - The record date for the dividend is set for November 26, 2025 [2] - The ex-dividend date and the date of cash dividend payment are both scheduled for November 27, 2025 [2]

南京证券股份有限公司（以下简称"保荐机构"）作为南京麦澜德医疗科技 股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票并上市及持 续督导的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，对 麦澜德 2025 年前三季度利润分配所涉及的差异化权益分派事项进行了核查，发 表如下意见： 一、本次差异化权益分派的原因 公司于 2023 年 8 月 22 日召开第一届董事会第二十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司通过集中竞价交易 方式回购公司已发行的人民币普通股（A 股），回购股份的资金总额不低于人民 币 2,000 万元（含），不超过人民币 4,000 万元（含），回购股份的价格不超过 人民币 50 元/股（含），回购股份的期限自董事会审议通过本次回购股份方案之 日起 12 个月内。公司于 2024 年 5 月 31 日完成此次回购，本次累计回购股份 1,110,000 股，回购金额合计 3,220.5070 万元。 公司于 2024 年 7 月 1 日召开第二届董事会第八次 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-048 南京麦澜德医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/26 | 2025/11/27 | 2025/11/27 | 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 11 月 7 日的2025年第三次临时股东会审议通 过。 二、分配方案 1. 发放年度：2025年前三季度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（南 京麦澜德医疗科技股份有限公司回购专用证券账户除外）。 根据中国证监会《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等有关规定，公司回购专用账户中的股份，不享有 股东会表决权 ...

Core Viewpoint - The company announced a share buyback of 2.19% of its total shares and plans to distribute cash dividends to shareholders in 2025 [1] Group 1: Share Buyback - As of the date of the verification opinion, the company has repurchased a total of 2,192,100 shares, accounting for 2.19% of the total share capital [1] Group 2: Dividend Distribution - For the fiscal year 2025, the company intends to distribute a cash dividend of 3 yuan (including tax) for every 10 shares based on the total share capital after excluding the shares in the buyback account [1] - As of October 23, 2025, the total number of shares participating in the dividend distribution is 97,807,900, with a total cash dividend of 29,342,400 yuan (including tax) planned [1] - The company will not conduct capital reserve transfers to increase share capital or issue bonus shares [1] Group 3: Compliance and Assurance - The sponsor institution believes that this distribution complies with regulations and does not harm the interests of the company and its shareholders [1]

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]

Group 1 - The core point of the news is that 麦澜德 (688273) has seen a net financing increase of 66.9 million yuan on November 10, with a total financing balance of 1.24 billion yuan, indicating a positive trend in investor interest [1][2][3] - In the last three trading days, 麦澜德 has accumulated a net financing buy of 330.68 million yuan, showing consistent demand from investors [1] - Over the past 20 trading days, there have been 11 days with net financing purchases, reflecting a sustained interest in the stock [1] Group 2 - The financing balance on November 10 was 1.24 billion yuan, which is an increase of 0.54% from the previous day [2][3] - The financing net purchases for the previous trading days were 159.72 million yuan on November 7 and 104.06 million yuan on November 6, indicating a growing trend in financing activity [2][3] - The financing balance has shown a steady increase over the past few days, with a notable rise from 1.20 billion yuan on November 4 to 1.24 billion yuan on November 10 [2][3]

Core Insights - Jiangning High-tech Zone has significantly improved its competitiveness ranking, moving up 4 places to 13th in the 2024 National Biopharmaceutical Industry Park Competitiveness Ranking released at the 2025 China Biotechnology Innovation Conference [3][4] - The ranking is based on a comprehensive evaluation of various dimensions including environment, industry, technology, talent, and cooperation, aimed at promoting the development and transformation of China's biopharmaceutical industry clusters [3] Group 1: Industry Overview - Jiangning High-tech Zone is recognized as a key cluster for the biopharmaceutical industry in the Yangtze River Delta, positioning biopharmaceuticals as its primary industry for regional transformation [3] - The park has attracted nearly 400 pharmaceutical companies, covering six major sectors including new drug development, cell and gene therapy, and high-end medical devices [3] Group 2: Performance Metrics - In 2024, the park successfully listed two Class 1 innovative drugs, with the pharmaceutical industry's revenue growth exceeding 30%, leading the city [3] - By the beginning of 2025, Jiangsu Province's first Class 1 innovative drug was developed in this zone, with a nearly 40% revenue growth for the first three quarters of the year, showcasing the industry's explosive growth potential [3][4] Group 3: Strategic Focus Areas - Jiangning High-tech Zone is strategically focusing on four emerging sectors: cell and gene therapy, nuclear medicine, beauty and health, and brain-computer interfaces, employing a model of "leading enterprises + chain extension + ecosystem construction" to build a competitive industrial cluster [4] - In the cell and gene therapy sector, the zone has established a complete industrial chain from gene synthesis to commercial production, leveraging leading companies such as Genscript and Ruigen Biotech [4] - The nuclear medicine sector aims to create a comprehensive ecosystem in collaboration with GE Healthcare and Dongcheng Andico, focusing on the entire production chain from target discovery to clinical transformation [4]

Core Viewpoint - Nanjing Medlander Medical Technology Co., Ltd. will hold a Q3 2025 earnings presentation on November 18, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation is scheduled for November 18, 2025, from 9:00 to 10:00 AM [2][4]. - The event will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][4]. - Investors can submit questions from November 11 to November 17, 2025, through the Roadshow Center website or via the company's email [5][6]. Group 2: Company Governance - The presentation will include participation from key executives, including the Chairman, General Manager, and Financial Director [4]. - The company assures that the content of the announcement is accurate and complete, with no misleading statements [1][8]. Group 3: Shareholder Meeting - A temporary shareholder meeting was held on November 7, 2025, with all resolutions passed without any objections [9][10]. - The meeting was conducted in compliance with relevant laws and regulations, ensuring its legality and validity [11][14]. - Key resolutions included profit distribution and changes to the company's registered address [13].

证券代码：688273 证券简称：麦澜德 公告编号：2025-047 南京麦澜德医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 18 日 （星期二） 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 23 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-046 南京麦澜德医疗科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 7 日 （二） 股东会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 60,493,804 | | 普通股股东所持有表决权数量 | 60,493,804 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.85 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.85 | （四） 表决方式 ...